Want to see RBGLY full AI Analyst Report?
RBGLY Stock Chart & Stats
$15.72
$0.07(0.58%)
At close: 4:00 PM EST
$15.72
$0.07(0.58%)
Day’s Range― - ―
52-Week Range$11.97 - $17.61
Previous CloseN/A
VolumeN/A
Average Volume (3M)20.41K
Market Cap
$43.47B
Enterprise Value$35.70B
Total Cash (Recent Filing)$1.95B
Total Debt (Recent Filing)$8.42B
Price to Earnings (P/E)12.3
Beta0.11
Next Earnings
Jul 29, 2026EPS Estimate
0.4Next Dividend Ex-DateN/A
Dividend Yield3.33%
Share Statistics
EPS (TTM)0.96
Shares Outstanding3,175,244,100
10 Day Avg. Volume0
30 Day Avg. Volume20,409
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.08
Price to Sales (P/S)2.83
P/FCF Ratio22.79
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue2.52
Enterprise Value/Gross Profit4.15
Enterprise Value/Ebitda7.60
Forecast
1Y Price Target
$14.60Price Target Upside-7.12% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.89
Revenue Forecast (FY)$17.04B
Bulls Say, Bears Say
Bulls Say
Emerging Markets GrowthEmerging markets delivered strong double-digit like-for-like growth and margin expansion, reflecting durable structural demand, higher online penetration and favorable mix in China and India. This regional outperformance diversifies revenue, supports long-term margin resilience and reduces reliance on mature markets.
Cost-savings Program (Fuel For Growth)The Fuel for Growth program produced meaningful, repeatable fixed-cost savings (~150bps) while enabling higher brand investment. Structural productivity gains underpin sustainable margin improvement, fund innovation spend, and provide a reliable lever to offset cyclical headwinds without sacrificing long-term growth initiatives.
Innovation And Product PipelineNotable R&D success including a rare FDA-approved NDA and multiple brand extensions demonstrates differentiated innovation capability. A strong pipeline and successful rollouts support premiumization, category expansion and durable revenue mix improvement, enhancing pricing power and long-term margin potential.
Bears Say
Rising LeverageManagement expects leverage to increase materially toward ~2.5x in the near term, on top of historically meaningful debt balances. Higher leverage reduces financial flexibility, increases refinancing and interest-rate exposure, and limits the company's ability to invest or absorb shocks if revenue or cash flow weaken.
Free Cash Flow PressureFCF generation remains positive but declined in 2025 with conversion slipping to ~71%, driven by elevated CapEx and restructuring cash costs. Reduced absolute FCF constrains deleveraging and return-of-capital flexibility and raises sensitivity to margin or sales setbacks over the medium term.
Stranded Costs & Fixed-cost PressureThe Essential Home divestment leaves stranded costs that management aims to offset via Fuel for Growth, yet fixed costs are expected to rise in 2026 before improving. This execution dependence creates margin risk: failure to fully recover stranded costs would compress margins or force deeper cuts to investment or marketing.
RBGLY FAQ
What was Reckitt Benckiser Group’s price range in the past 12 months?
Reckitt Benckiser Group lowest stock price was $11.97 and its highest was $17.61 in the past 12 months.
What is Reckitt Benckiser Group’s market cap?
Reckitt Benckiser Group’s market cap is $43.47B.
When is Reckitt Benckiser Group’s upcoming earnings report date?
Reckitt Benckiser Group’s upcoming earnings report date is Jul 29, 2026 which is in 24 days.
How were Reckitt Benckiser Group’s earnings last quarter?
Reckitt Benckiser Group released its earnings results on Mar 05, 2026. The company reported $0.491 earnings per share for the quarter, missing the consensus estimate of $0.511 by -$0.02.
Is Reckitt Benckiser Group overvalued?
According to Wall Street analysts Reckitt Benckiser Group’s price is currently Overvalued.
Does Reckitt Benckiser Group pay dividends?
Reckitt Benckiser Group pays a Quarterly dividend of $0.342 which represents an annual dividend yield of 3.33%. See more information on Reckitt Benckiser Group dividends here
What is Reckitt Benckiser Group’s EPS estimate?
Reckitt Benckiser Group’s EPS estimate is 0.4.
How many shares outstanding does Reckitt Benckiser Group have?
Reckitt Benckiser Group has 3,175,244,100 shares outstanding.
What happened to Reckitt Benckiser Group’s price movement after its last earnings report?
Reckitt Benckiser Group reported an EPS of $0.491 in its last earnings report, missing expectations of $0.511. Following the earnings report the stock price went down -6.097%.
Which hedge fund is a major shareholder of Reckitt Benckiser Group?
Currently, no hedge funds are holding shares in RBGLY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Reckitt Benckiser Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$14.60 (-7.12% Downside)
$14.60 (-7.12% Downside)
Blogger Sentiment
Bullish
RBGLY Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.22%
12-Months-Change
Fundamentals
Return on Equity
45.27%
Trailing 12-Months
Asset Growth
6.42%
Trailing 12-Months
Company Description
Reckitt Benckiser Group
Reckitt Benckiser Group Plc engages in the manufacture and trade of consumer brand products including Air Wick, Calgon, Cillit Bang, Clearasil, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, and Woolite. It operates through the following segments: Hygiene, Health, and Nutrition. The company was founded by Isaac Reckitt in 1840 and is headquartered in Slough, the United Kingdom.
RBGLY Company Deck
RBGLY Earnings Call
Q4 2026
0:00 / 0:00
RBGLY Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$14.60
▼(-7.12% Downside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
―
Insiders
0.01% Mutual Funds
0.04% Other Institutional Investors
99.87% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---







